Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Ependymoma

"Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Ependymoma is a rare type of tumor of the brain or spinal cord. It can happen in both children and adults. In children, these tumors tend to be in the brain. In adults, they're often in the spinal cord. Literature suggest that people with a genetic disorder called neurofibromatosis type 2 (NF2) have a higher risk of developing an ependymoma.

The World Health Organization (WHO) classifies ependymoma into 3 grades:

Grade I (1): Subependymoma

Grade II (2): Ependymoma or myxopapillary ependymoma

Grade III (3): Anaplastic ependymoma

Grade I is the slowest growing ependymoma, Grade III is fast growing.

According to Thelansis, These tumors have an incident rate of 0.43 patients per 100 000 population in the United States, accounting for 1.8% of all primary brain tumors.

Competitive landscape of Ependymoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Ependymoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Ependymoma Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No        Asset        Company        Stage

1        WP1066        Moleculin Biotech, Inc.        Phase 1

2        valacyclovir        Candel Therapeutics, Inc.        Phase 1

3        Optune NovoTTF-200A System        Hackensack Meridian Health        Phase 1

4        Nivolumab        Bristol-Myers Squibb        Phase 2

5        Gemcitabine        Novartis Pharmaceuticals        Phase 1

6        Selumetinib        AstraZeneca        Phase 2

7        ONC206        Oncoceutics, Inc.        Phase 1

8        Brigatinib        Takeda        Phase 2

9        Indoximod        NewLink Genetics Corporation        Phase 1

10        AXL1717        Axelar AB        Phase 2

11        Polio/Rhinovirus Recombinant (PVSRIPO)        Istari Oncology, Inc.        Phase 1

12        Abemaciclib        Eli Lilly and Company        Phase 1

13        Alisertib        Millennium Pharmaceuticals, Inc.        Phase 1

14        BXQ-350        Bexion Pharmaceuticals, Inc.        Phase 1

15        exatecan mesylate        Daiichi Sankyo, Inc.        Phase 1

16        Fentanyl sublingual spray        INSYS Therapeutics Inc        Phase 3

17        5-Aminolevuline Acid        DUSA Pharmaceuticals, Inc.        Phase 2

18        CLR 131        Cellectar Biosciences, Inc.        Phase 1

19        Pomalidomide        Celgene        Phase 2

20        tozuleristide        Blaze Bioscience Inc.        Phase 2

21        Photofrin        Pinnacle Biologics Inc.        Phase 1

22        carmustine in ethanol        Direct Therapeutics        Phase 2

23        Lapatinib        GlaxoSmithKline        Phase 2

24        temozolomide        Jazz Pharmaceuticals        Phase 1

25        VEGF inhibitor PTC299        PTC Therapeutics        Phase 1

26        carboplatin        Amgen        Phase 1"